Studies in mice have identified EGCG as a potential inhibitor of ferroptosis by increasing FTH/L (Ferritin H/L), NRF2 (nuclear factor erythroid 2-related factor 2), and GPX4 expression, suggesting that it could be considered a therapeutic agent for liver diseases induced by iron overload [90]. This evidence concerns the gene FTH1 and liver disorder.